Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review

被引:40
作者
Toivonen, Kirsti I. [1 ]
Williamson, Tamara M. [1 ]
Carlson, Linda E. [2 ,3 ]
Walker, Lauren M. [2 ,3 ]
Campbell, Tavis S. [1 ]
机构
[1] Univ Calgary, Dept Psychol, Calgary, AB T2N 1N4, Canada
[2] Univ Calgary, Dept Oncol, Calgary, AB T2N 1N4, Canada
[3] Tom Baker Canc Clin, Dept Psychosocial Resources, Holy Cross Site, Calgary, AB T2S 3C1, Canada
基金
加拿大健康研究院;
关键词
review; adherence; breast cancer; adjuvant endocrine therapy; ORAL HORMONAL-THERAPY; QUALITY-OF-LIFE; MEDICATION ADHERENCE; SELF-EFFICACY; AROMATASE INHIBITORS; POSTMENOPAUSAL WOMEN; PSYCHOSOCIAL FACTORS; EARLY DISCONTINUATION; TAMOXIFEN THERAPY; CLINICAL-PRACTICE;
D O I
10.3390/cancers13010107
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adjuvant endocrine therapy (AET) reduces risk of breast cancer recurrence. However, suboptimal adherence and persistence to AET remain important clinical issues. Understanding factors associated with adherence may help inform efforts to improve use of AET as prescribed. The present systematic review examined potentially modifiable factors associated with adherence to AET in accordance with PRISMA guidelines (PROSPERO registration ID: CRD42019124200). All studies were included, whether factors were significantly associated with adherence or results were null. This review also accounted for the frequency with which a potentially modifiable factor was examined and whether univariate or multivariate models were used. This review also examined whether methodological or sample characteristics were associated with the likelihood of a factor being associated with AET adherence. A total of 68 articles were included. Potentially modifiable factors were grouped into six categories: side effects, attitudes toward AET, psychological factors, healthcare provider-related factors, sociocultural factors, and general/quality of life factors. Side effects were less likely to be associated with adherence in studies with retrospective or cross-sectional than prospective designs. Self-efficacy (psychological factor) and positive decisional balance (attitude toward AET) were the only potentially modifiable factors examined >= 10 times and associated with adherence or persistence >= 75% of the time in both univariate and multivariate models. Self-efficacy and decisional balance (i.e., weight of pros vs. cons) were the potentially modifiable factors most consistently associated with adherence, and hence may be worth focusing on as targets for interventions to improve AET adherence among breast cancer survivors.
引用
收藏
页码:1 / 22
页数:22
相关论文
共 50 条
  • [31] Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors
    Heiney, Sue P.
    Truman, Samantha
    Babatunde, Oluwole A.
    Felder, Tisha M.
    Eberth, Jan M.
    Crouch, Elizabeth
    Wickersham, Karen E.
    Adams, Swann Arp
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (07): : 504 - 509
  • [32] Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement
    Gao, Pin
    You, Lili
    Wu, Di
    Shi, Aiping
    Miao, Qing
    Rana, Ujala
    Martin, Dustin Paul
    Du, Ye
    Zhao, Gang
    Han, Bing
    Zheng, Chao
    Fan, Zhimin
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 887 - 897
  • [33] Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory
    AlOmeir, Othman
    Patel, Nilesh
    Donyai, Parastou
    [J]. SUPPORTIVE CARE IN CANCER, 2020, 28 (11) : 5075 - 5084
  • [34] Beliefs about medicines' association with endocrine therapy adherence in early breast cancer survivors in Croatia
    Okrosa, Ana Dugonjic
    Silovski, Tajana
    Plavetic, Natalija Dedic
    Silovski, Hrvoje
    Kovacic, Ana
    Mucalo, Iva
    [J]. ACTA PHARMACEUTICA, 2023, 73 (04) : 673 - 689
  • [35] Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
    Makubate, B.
    Donnan, P. T.
    Dewar, J. A.
    Thompson, A. M.
    McCowan, C.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (07) : 1515 - 1524
  • [36] Beliefs about medicines and adherence in women with breast cancer on adjuvant endocrine therapy
    Tan, Eng Hooi
    Wong, Andrea Li Ann
    Tan, Chuan Chien
    Wong, Patrick
    Tan, Sing Huang
    Ang, Li En Yvonne
    Lim, Siew Eng
    Chong, Wan Qin
    Ho, Jingshan
    Lee, Soo Chin
    Tai, Bee Choo
    [J]. JOURNAL OF HEALTH PSYCHOLOGY, 2022, 27 (05) : 1111 - 1124
  • [37] The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review
    Fleming, Leanne
    Agnew, Sommer
    Peddie, Nicola
    Crawford, Megan
    Dixon, Diane
    MacPherson, Iain
    [J]. BREAST, 2022, 64 : 63 - 84
  • [38] The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients
    Farias, Albert J.
    Hansen, Ryan N.
    Zeliadt, Steven B.
    Ornelas, India J.
    Li, Christopher I.
    Thompson, Beti
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (07): : 708 - 715
  • [39] A systematic review of interventions to improve adherence to endocrine therapy
    Heiney, Sue P.
    Parker, Pearman D.
    Felder, Tisha M.
    Adams, Swann Arp
    Omofuma, Omonefe O.
    Hulett, Jennifer M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (03) : 499 - 510
  • [40] Influence of Patient and Treatment Factors on Adherence to Adjuvant Endocrine Therapy in Breast Cancer
    Bender, Catherine M.
    Gentry, Amanda L.
    Brufsky, Adam M.
    Casillo, Frances E.
    Cohen, Susan M.
    Dailey, Meredith M.
    Donovan, Heidi S.
    Dunbar-Jacob, Jacqueline
    Jankowitz, Rachel C.
    Rosenzweig, Margaret Q.
    Sherwood, Paula R.
    Sereika, Susan M.
    [J]. ONCOLOGY NURSING FORUM, 2014, 41 (03) : 274 - 285